|Purdue University researchers have developed an off-the-shelf treatment for targeted cancer immunotherapy. Natural killer (NK) cells are innate lymphoid cells that can be used as targeted immunotherapy for various cancers, but the lack of reliable resources for large scale production and supply of NK cells for clinical use has limited their application in cell therapy. Purdue researchers genetically engineered human pluripotent stem cells (hPSCs) that overexpress ID2, a transcription factor that greatly promotes NK cell generation, under a chemically-defined, feeder-free culture condition. The ID2-hPSC-derived NK cells contain NK cell-specific markers and show effective tumor-killing activity, comparable to NK cells derived from wild-type hPSCs. Further enhancements in antitumor activity were seen when hPSC-NK cells were engineered with a dual anti-PD-L1 CAR and universal anti-fluorescein (FITC) CAR. The use of the universal CAR design allows for targeting of solid tumors and a more widespread targeting of all cancers. The hPSC CAR-NK engineering platform provides a scalable strategy for enhanced generation of off-the-shelf NK cells for use in clinical applications for cancer treatment.
-Modular and scalable
-Off-the-shelf, no long waiting period for patients
-No autoimmune reactivity or cell rejection
-Solid Tumor therapy
Temporal Expression of Transcription Factor ID2 Improves Natural Killer Cell Differentiation from Human Pluripotent Stem Cells.
ACS Synth. Biol. 2022, 11, 6, 2001–2008
Aug 17, 2022
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486